| [1] |
Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
|
| [2] |
Zhang ZM, Lai EC, Zhang C, et al. The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J]. Int J Surg, 2015(20):8-16.
|
| [3] |
Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127):1301-1314
|
| [4] |
Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma[J]. Hepatol Int, 2010, 4(2):439-474.
|
| [5] |
Liang L, Chen TH, Li C, et al. A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. HPB, 2018, 20(12):1119-1129.
|
| [6] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中国实用外科杂志, 2020, 40(2):121-138.
|
| [7] |
Cheng S, Chen M, Cai J, et al. Chinese Expert Consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018 edition)[J]. Liver cancer, 2020, 9(1):28-40.
|
| [8] |
Kokudo N, Takemura N, Hasegawa K, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update[J]. Hepatol Res, 2019, 49(10):1109-1113.
|
| [9] |
Yau T, Tang VY, Yao TJ, et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma[J]. Gastroenterology, 2014, 146(7):1691-1700, e3.
|
| [10] |
Sakamoto K, Nagano H. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus[J]. Hepatol Res, 2017, 47(10):957-962.
|
| [11] |
Zhang XP, Gao YZ, Chen ZH, et al. An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: a multicenter study[J]. Hepatology, 2019, 69(5):2076-2090.
|
| [12] |
Chong JU, Choi GH, Han DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(11):3308-3315.
|
| [13] |
Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24):2141-2151.
|
| [14] |
Kokudo T, Hasegawa K, Matsuyama Y, et al. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion[J]. J Hepatol, 2016, 65(5):938-943.
|
| [15] |
Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan[J]. Hepataol Res, 2008, 38(1):37-51.
|
| [16] |
董家鸿, 郑树森, 陈孝平, 等. 肝切除术前肝脏储备功能评估的专家共识(2011版)[J]. 中华消化外科杂志, 2011, 10(1):20-25.
|
| [17] |
Dahiya D, Wu TJ, Lee CY, et al. Minor versus major hepatic resection for small hepatocellular carcinoma (HCC) in cirrhotic patients: a 20-year experience[J]. Surgery, 2010, 147(5):676-685.
|
| [18] |
Couinaud C. Absence of portal bifurcation[J]. J Chir, 1993, 130(3):111-115.
|
| [19] |
Wei XB, Xu J, Li N, et al. The role of three-dimensional imaging in optimizing diagnosis, classification and surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]. HPB, 2016, 18(3):287-295.
|
| [20] |
Inoue Y, Hasegawa K, Ishizawa T, et al. Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma?[J]. Surgery, 2009, 145(1):9-19.
|
| [21] |
Zhang YF, Le Y, Wei W, et al. Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: a propensityscore analysis[J]. Oncotarget, 2016, 7(25):38845-38856.
|
| [22] |
Chok KS, Cheung TT, Chan SC, et al. Management of HCC with PVTH surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis[J]. World J Surg, 2014, 38(2):490-496.
|
| [23] |
Ban D, Shimada K, Yamamoto Y, et al. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein[J]. J Gastrointest Surg, 2009, 13(11):1921-1928.
|
| [24] |
Peng SY, Wang XA, Huang CY, et al. Better surgical treatment method for hepatocellular carcinoma with portal vein tumor thrombus[J]. World J Gastroenterol, 2018, 24(40):4527-4535.
|
| [25] |
Xi T, Lai EC, Min AR, et al. Adjuvant transarterial chemoembolization after curative resection of hepatocellular carcinoma: a non-randomized comparative study[J]. Hepatogastroenterology, 2012, 59(116):1198-1203.
|
| [26] |
Sun JJ, Wang K, Zhang CZ, et al. Postoperative adjuvant transcatheter arterial chemoembolization after R0 hepatectomy improves outcomes of patients who have hepatocellular carcinoma with microvascular invasion[J]. Ann Surg Oncol, 2016, 23(4):1344-1351.
|
| [27] |
Peng BG, He Q, Li JP, et al. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus[J]. Am J Surg, 2009, 198(3):313-318.
|
| [28] |
Mornex F, Girard N, Beziat C, et al. Feasibility and effificacy of high dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French Phase Ⅱ RTF-1 trial[J]. Int J Radiat Oncol Biol Phys, 2006, 66(4):1152-1158.
|
| [29] |
Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2015, 16(13):1344-1354.
|
| [30] |
Zhang W, Zhao G, Wei K, et al. Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience[J]. BioSci Trends, 2014, 8(6):333-338.
|
| [31] |
Zhang XP, Chai ZT, Gao YZ, et al. Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis[J]. HPB, 2019, 21(12):1687-1696.
|
| [32] |
Xia F, Wu LL, Lau WY, et al. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients[J]. World J Gastroenterol, 2016, 22(23):5384-5392.
|
| [33] |
Guo WX, Guo L, Wang K, et al. Postoperative sorafenib prolongs survival of hepatocellular carcinoma patients with Portal vein tumor thrombus following hepatic resection[J]. Int J Clin Exp Med, 2017, 10(1):1615-1623.
|